Insights & Updates

Offspring Biosciences | Tissue Insights™ | Preclinical Safety There is a decision point in almost every therapeutic antibody program that receives far less strategic attention than it deserves. It sits just before the formal GLP Tissue Cross-Reactivity (TCR) study - the FDA and EMA-mandated IHC screen of the drug candidate across a defined panel of normal human organ tissues, without which an IND cannot be filed. Most program teams treat this as a fixed milestone: select a

For over a decade, the pharmaceutical industry has universally admired the structured translational frameworks pioneered by industry leaders. When AstraZeneca instituted the "5R Framework" (Right Target, Right Tissue, Right Safety, Right Patient, Right Commercial) and Pfizer deployed their "Three Pillars of Survival" (now the SOCA paradigm), the results were undeniable. AstraZeneca drove their Phase III success rate from a dismal 4% to 19% (1), while Pfizer saw a tenfold impr

Neurology is one of the most complex and challenging frontiers in medicine, encompassing a vast spectrum of disorders that affect the central and peripheral nervous system, behavioral and mood changes, and extending changes in hormones and the microbiome. This includes progressive neurodegenerative conditions like Alzheimer’s Disease and Parkinson’s Disease, defined by the toxic aggregation of proteins like Amyloid-beta and alpha-synuclein; autoimmune disorders like Multiple

For translational leaders, generating decision-quality data before risking millions in clinical trials is crucial. De-Risk Antibody Development with Tissue Insights Platform.

Human Tissue Analysis in CNS drug development helps to bridge the translational gap and de-risk clinical development. New research on Alzheimers Disease, Palsy, Parkinsons, Multi System Atrophy and more offer insights into treatment development.